Back to discover
Drug

Cysteine

In clinical development
Emerging researchEarly-to-mid developmentRising momentum
Also known as (2R)-2-amino-3-mercaptopropanoic acid, (2R)-2-amino-3-sulfanylpropanoic acid, (R)-2-Amino-3-mercaptopropanoic acid, Amino-Cerv+21 more

(2R)-2-amino-3-mercaptopropanoic acid, (2R)-2-amino-3-sulfanylpropanoic acid, (R)-2-Amino-3-mercaptopropanoic acid, Amino-Cerv, Cisteina, Cisteinum, Cys, Elcys, Freamine III 10, Free Cysteine, Hepatamine 8, Hepatasol, L-2-Amino-3-mercaptopropionic acid, L-CYSTEINE, L-Cys, L-Cystein, L-Zystein, Nephramine, Nouress, PremaSol, ProcalAmine 3, Trophamine, Trophamine 10 %, Trophamine 6 %, Cysteinum.

3
Research papers
Latest activity
beta

Recent clinical, regulatory, research and industry developments relating to this drug.

Profiling the landscape of cysteine posttranslational modifications in brain aging and neurodegeneration.

Research2025-08-30Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics

Optimization of Blood Levels of 25(OH)-Vitamin D in African Americans

Clinical trial2022-10-31Completed · ClinicalTrials.gov

Profile

Identifiers & mechanism

Canonical identifiers, marketed brand names and mechanism, resolved across RxNorm, ChEMBL and ATC.

Canonical name
Cysteine
Aliases & brands
(2R)-2-amino-3-mercaptopropanoic acid(2R)-2-amino-3-sulfanylpropanoic acid(R)-2-Amino-3-mercaptopropanoic acidAmino-CervCisteinaCisteinumCysElcysFreamine III 10Free CysteineHepatamine 8HepatasolL-2-Amino-3-mercaptopropionic acidL-CYSTEINEL-CysL-CysteinL-ZysteinNephramineNouressPremaSolProcalAmine 3TrophamineTrophamine 10 %Trophamine 6 %Cysteinum
RxNorm CUI
3024
ChEMBL ID
CHEMBL863
UNII
K848JZ4886

Clinical trials

2 trials

The current development programme across all trial phases — status mix, phase distribution and the late-stage studies shaping the evidence base.

Development programme
CLINICALTRIALS.GOV · LIVE REGISTRY
2
registered trials across all phases
LATEST COMPLETION 2022
1
Late-stage (III+)
1
Completed
1
Discontinued
PHASE DISTRIBUTIONn = 2
Early Phase 11Phase N / A1

Recent completions

Trials that read out recently, adding to the completed evidence base.

Optimization of Blood Levels of 25(OH)-Vitamin D in African Americans

CompletedPH ILouisiana State University Health Sciences Center Shreveportn=1652022

Research activity

3 papers

Key research shaping understanding of this drug, combining the latest publications with the most influential evidence.

Publications over time
20192025
Most influential
Recent papers
Major research themes7
Aging1Brain1Cysteine1Lipoylation1Neoplasms1Neurodegenerative Diseases1Protein Processing, Post-Translational1
Journals, researchers & institutions
Top journals
  • Frontiers in immunology1
  • Nature communications1
  • Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics1
Leading researchers
  • Chen Y1
  • Filipovic MR1
  • Fu XW1
  • Han C1
  • Kong LY1
  • Li Y1
  • Liao ST1
  • Wang JS1
Leading institutions
free-text, unnormalised
  • Center for Molecular Metabolism1
  • Chongqing University Cancer Hospital1
  • Jiangsu Key Laboratory of Bioactive Natural Product Research and State Key Laboratory of Natural Medicines1
  • School of Molecular Biosciences1

Related drugs

1 matches

Drugs sharing diseases, protein targets and literature with this one. Ranked by graph evidence (shared targets + diseases weighted above co-mentions).

Studied across 2 of the same disease areas as Cysteine in the shared literature.

2 shared diseases1 shared paper
References & data sources
  • RxNorm (U.S. National Library of Medicine) — drug identity
  • ChEMBL (EMBL-EBI) & UniProt — pharmacology and targets
  • Europe PMC — research literature
  • ClinicalTrials.gov — clinical trials